Sugi Predict

Sugi Predict / Targets / CTRL

CTRL

Chymotrypsin-like protease CTRL-1 · P40313 · CTRL on Sugi Atlas →

7,788 patent compounds predicted against CTRL, 6,744 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8143396 SCHEMBL8143396 0.87 14/20
SCHEMBL8137594 SCHEMBL8137594 0.74 14/20
SCHEMBL8135090 SCHEMBL8135090 0.92 12/20
SCHEMBL8138776 SCHEMBL8138776 0.90 12/20
SCHEMBL8135866 SCHEMBL8135866 0.88 12/20
SCHEMBL8134932 SCHEMBL8134932 0.82 12/20
SCHEMBL8130815 SCHEMBL8130815 0.79 12/20
SCHEMBL8122595 SCHEMBL8122595 0.77 12/20
SCHEMBL8129093 SCHEMBL8129093 0.75 12/20
SCHEMBL8123039 SCHEMBL8123039 0.90 11/20
SCHEMBL8135868 SCHEMBL8135868 0.90 11/20
SCHEMBL8138781 SCHEMBL8138781 0.87 11/20
SCHEMBL8148206 SCHEMBL8148206 0.84 11/20
SCHEMBL8141331 SCHEMBL8141331 0.83 11/20
SCHEMBL8132667 SCHEMBL8132667 0.83 11/20
SCHEMBL8141353 SCHEMBL8141353 0.83 11/20
SCHEMBL8145556 SCHEMBL8145556 0.81 11/20
SCHEMBL8131859 SCHEMBL8131859 0.77 11/20
SCHEMBL8132138 SCHEMBL8132138 0.74 11/20
SCHEMBL8143691 SCHEMBL8143691 0.72 11/20

Clinical trials — most relevant to CTRL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function PHASE4COMPLETED
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease PHASE4ACTIVE_NOT_RECRUITING
A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection PHASE4UNKNOWN
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema PHASE3COMPLETED
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults PHASE3COMPLETED
Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection PHASE3WITHDRAWN
Collagenase in the Treatment of Dupuytrens Disease PHASE3COMPLETED
Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease PHASE3COMPLETED
Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease PHASE3COMPLETED
Deposition of Inhaled Prolastin in Cystic Fibrosis Patients PHASE2COMPLETED
A Phase IIa Study With Escalating Dose of MS1819-SD PHASE2COMPLETED
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI PHASE1/PHASE2COMPLETED
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor PHASE2COMPLETED
Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns PHASE2RECRUITING
A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy PHASE2COMPLETED
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration PHASE2COMPLETED
Effects of Topical SLPI on Skin Wounds PHASE1COMPLETED
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy PHASE1NOT_YET_RECRUITING
Pharmacokinetic Study of ARALAST (Human Alpha1- PI) PHASE1COMPLETED
Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP PHASE1COMPLETED
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
Effect of Microbial Protease Supplementation on Postprandial Amino Acid Levels nanCOMPLETED
Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations nanRECRUITING
Peri-implantitis and MMP-8 nanCOMPLETED
Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis nanCOMPLETED
Synovial Fluid Bank From Arthritic Patients nanRECRUITING
In Vivo Effects of Amylase Trypsin Inhibitors nanUNKNOWN
HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients nanCOMPLETED
Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery nanRECRUITING
Evaluation of a Standardized Protocol for Thrombin Generation Assay nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CTRL binder may also engage these)

ProteinNameSimilarity
P80646 — 0.990 P80646 →
P04813 — 0.984 P04813 →
P47796 — 0.979 P47796 →
P00766 — 0.977 P00766 →
CTRB1 Chymotrypsinogen B 0.976 landscape →
CTRB2 Chymotrypsinogen B2 (EC 3.4.21.1) [Cleaved in 0.976 landscape →
P00767 — 0.976 P00767 →
P70059 — 0.971 P70059 →
P07338 — 0.970 P07338 →
Q9CR35 — 0.970 Q9CR35 →
P05208 — 0.969 P05208 →
P06871 — 0.967 P06871 →
P80009 — 0.966 P80009 →
B8V7S0 — 0.966 B8V7S0 →
P29786 — 0.966 P29786 →
Q28153 — 0.965 Q28153 →
P07146 — 0.965 P07146 →
P16049 — 0.963 P16049 →
P08426 — 0.963 P08426 →
P08218 — 0.963 P08218 →
Q9PT51 — 0.963 Q9PT51 →
Q9GL10 — 0.962 Q9GL10 →
P00773 — 0.962 P00773 →
P80010 — 0.962 P80010 →
P00762 — 0.962 P00762 →
Q5R1M5 — 0.962 Q5R1M5 →
Q29463 — 0.962 Q29463 →
Q91041 — 0.961 Q91041 →
P19799 — 0.961 P19799 →
P29787 — 0.961 P29787 →